NASDAQ$IRWD
Ironwood Pharmaceuticals Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported fourth quarter and full year results, achieving GAAP and non-GAAP net income of $175 million for the year and ending the year with $656 million in cash and cash equivalents.
Ironwood Pharmaceuticals reported its fourth quarter and full year 2022 results, with full year LINZESS U.S. net sales growth lower than expected due to inventory fluctuations, but delivered adjusted EBITDA guidance of over $250 million. The company ended the year with a strong balance sheet and is focused on investing in LINZESS and pursuing GI assets.
- 2022 GAAP and non-GAAP net income of $175 million
- 2022 adjusted EBITDA of $252 million
- Ended 2022 with $656 million in cash and cash equivalents
- FDA granted priority review to the sNDA for LINZESS for the treatment of functional constipation in pediatric patients aged 6 to 17 with a PDUFA date in the second quarter of 2023
Headline financials
Revenue & EPS history
Ironwood Pharmaceuticals · Revenue · Quarterly
$107M
Revenue by segment
Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020
- LINZESS Collaboration$71M—100.0%
Forward guidance
Ironwood anticipates a number of exciting milestones this year, and believe Ironwood is well positioned to deliver long term growth and value to patients and shareholders. Ironwood has assumed that it will not incur material expenses related to business development activities in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-1.0%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-1.2%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+32.8%
Q3 2025
Best reaction
-29.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.9% | -15.5% | -31.5% | |
| Q4 2025 | -11.4% | -5.8% | -19.3% | |
| Q3 2025 | +32.8% | +63.5% | +92.2% | |
| Q1 2025 | -4.4% | +0.0% | +5.1% | |
| Q4 2024 | -5.3% | -12.9% | -17.5% | |
| Q3 2024 | -1.6% | -12.9% | -31.9% | |
| Q2 2024 | -29.5% | -25.3% | -25.0% | |
| Q1 2024 | -13.8% | -18.3% | -21.8% | |
| Q4 2023 | -5.6% | -4.0% | -41.6% | |
| Q3 2023 | +5.5% | +5.6% | +13.5% | |
| Q2 2023 | -15.3% | -11.3% | -24.2% | |
| Q1 2023 | +1.5% | -2.4% | +4.9% | |
| Q4 2022 | +5.8% | +3.9% | -7.4% | |
| Q3 2022 | +3.7% | +6.8% | +11.9% | |
| Q2 2022 | +5.9% | +5.6% | -2.9% | |
| Q1 2022 | -3.0% | -8.4% | -9.0% | |
| Q4 2021 | -2.5% | -1.2% | +13.5% | |
| Q3 2021 | +0.4% | -1.2% | -14.6% | |
| Q2 2021 | +3.2% | +4.3% | -1.5% | |
| Q1 2021 | +1.3% | +1.5% | +9.3% | |
| Q4 2020 | -7.0% | -6.6% | +12.3% | |
| Q3 2020 | +4.0% | +12.4% | +16.8% | |
| Q2 2020 | +5.8% | +3.0% | +1.5% | |
| Q1 2020 | -3.2% | +2.5% | -5.3% | |
| Q4 2019 | -3.2% | -2.9% | -18.3% | |
| Q3 2019 | +10.0% | +15.9% | +27.5% | |
| Q2 2019 | +2.6% | -0.8% | -10.0% | |
| Q1 2019 | -9.9% | -12.3% | -7.2% | |
| Q4 2018 | +5.4% | +15.1% | +3.1% | |
| Q3 2018 | -15.6% | -15.9% | -10.3% | |
| Q2 2018 | -1.1% | -1.9% | -1.1% | |
| Q1 2018 | +4.4% | +2.6% | +2.5% | |
| Q4 2017 | +6.0% | +2.4% | +6.0% | |
| Q3 2017 | +6.8% | +1.8% | +16.6% | |
| Q2 2017 | -12.8% | -15.5% | -9.0% | |
| Q1 2017 | +5.2% | +12.9% | +10.5% | |
| Q4 2016 | -1.6% | -4.2% | +0.1% | |
| Q3 2016 | +7.2% | +15.2% | +22.5% | |
| Q2 2016 | -6.0% | -7.7% | -6.9% | |
| Q1 2016 | +9.3% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | -0.1% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | -8.9% | — | — | |
| Q4 2012 | -7.7% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.8% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q1 2012 | -3.5% | — | — | |
| Q4 2011 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q3 2011 | -13.6% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q1 2010 | -3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro